FY guidance is $1.4b. HY1 is $677.4m. Your guess about chinese label revenue of $495 is also in line with what company said - they expect ~40-45% growth to continue for that segment. If to assume there is no growth/decline in any other segment it will give us ~$1.42b for the FY. So, even if they sell less IF in CBEC & ANZ by $20m this HY they still will meet the guidance. So, yes, lets hope they can do better in CBEC & ANZ in 2HY
Btw, if to believe a2nutrition.cn site they already increase their store count by 8k.
- Forums
- ASX - By Stock
- A2M
- Chart Update
Chart Update, page-18316
-
- There are more pages in this discussion • 6,915 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.87 |
Change
-0.015(0.22%) |
Mkt cap ! $4.959B |
Open | High | Low | Value | Volume |
$6.93 | $6.98 | $6.83 | $5.720M | 826.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 4533 | $6.86 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.87 | 10916 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 1531 | 6.850 |
23 | 23990 | 6.840 |
21 | 36948 | 6.830 |
17 | 37364 | 6.820 |
14 | 27616 | 6.810 |
Price($) | Vol. | No. |
---|---|---|
6.860 | 10447 | 17 |
6.870 | 27248 | 17 |
6.880 | 20716 | 15 |
6.890 | 25722 | 12 |
6.900 | 33084 | 14 |
Last trade - 14.03pm 15/07/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online